Free Trial
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel Free BGM Stock Alerts

BGM Group (BGM) Competitors

BGM Group logo
$10.75 +0.79 (+7.93%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$10.44 -0.31 (-2.88%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BGM vs. PLYX, PYPD, NTRB, CGTX, and ICCC

Should you buy BGM Group stock or one of its competitors? BGM Group's main competitors and comparable companies include Polaryx Therapeutics (PLYX), PolyPid (PYPD), Nutriband (NTRB), Cognition Therapeutics (CGTX), and ImmuCell (ICCC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BGM Group compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Company Net Margins Return on Equity Return on Assets
Polaryx TherapeuticsN/A N/A N/A
BGM Group N/A N/A N/A

In the previous week, BGM Group had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 2 mentions for BGM Group and 1 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.34 beat BGM Group's score of 0.00 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Polaryx Therapeutics Positive
BGM Group Neutral

Polaryx Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 283.33%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Polaryx Therapeutics is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Polaryx Therapeutics has higher earnings, but lower revenue than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Polaryx TherapeuticsN/AN/A-$8.98M-$0.08N/A
BGM Group$37.92M3.60-$19.94MN/AN/A

Summary

Polaryx Therapeutics beats BGM Group on 6 of the 8 factors compared between the two stocks.

How does BGM Group compare to PolyPid?

BGM Group (NASDAQ:BGM) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

BGM Group has higher revenue and earnings than PolyPid.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$37.92M3.60-$19.94MN/AN/A
PolyPidN/AN/A-$34.17M-$1.48N/A

In the previous week, PolyPid had 1 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for PolyPid and 2 mentions for BGM Group. PolyPid's average media sentiment score of 0.49 beat BGM Group's score of 0.00 indicating that PolyPid is being referred to more favorably in the news media.

Company Overall Sentiment
BGM Group Neutral
PolyPid Neutral

PolyPid has a consensus price target of $11.33, indicating a potential upside of 123.54%. Given PolyPid's stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
PolyPid
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

26.5% of PolyPid shares are owned by institutional investors. 58.7% of BGM Group shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BGM Group's return on equity of 0.00% beat PolyPid's return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
PolyPid N/A -311.08%-150.83%

BGM Group has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Summary

BGM Group and PolyPid tied by winning 6 of the 12 factors compared between the two stocks.

How does BGM Group compare to Nutriband?

BGM Group (NASDAQ:BGM) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

19.7% of Nutriband shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BGM Group has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market. Comparatively, Nutriband has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Nutriband has lower revenue, but higher earnings than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$37.92M3.60-$19.94MN/AN/A
Nutriband$2.04M39.64-$8.23M-$0.53N/A

BGM Group has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. BGM Group's return on equity of 0.00% beat Nutriband's return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
Nutriband -430.35%-109.07%-95.54%

In the previous week, Nutriband had 1 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for Nutriband and 2 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 equaled Nutriband'saverage media sentiment score.

Company Overall Sentiment
BGM Group Neutral
Nutriband Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nutriband
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Nutriband beats BGM Group on 6 of the 11 factors compared between the two stocks.

How does BGM Group compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

BGM Group has higher revenue and earnings than Cognition Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cognition TherapeuticsN/AN/A-$23.49M-$0.17N/A
BGM Group$37.92M3.60-$19.94MN/AN/A

Cognition Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 280.13%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cognition Therapeutics is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

43.3% of Cognition Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 58.7% of BGM Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BGM Group's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cognition TherapeuticsN/A -50.17% -40.22%
BGM Group N/A N/A N/A

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 2 articles in the media. Cognition Therapeutics' average media sentiment score of 0.00 equaled BGM Group'saverage media sentiment score.

Company Overall Sentiment
Cognition Therapeutics Neutral
BGM Group Neutral

Summary

BGM Group beats Cognition Therapeutics on 6 of the 10 factors compared between the two stocks.

How does BGM Group compare to ImmuCell?

BGM Group (NASDAQ:BGM) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

13.5% of ImmuCell shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ImmuCell has a net margin of 2.57% compared to BGM Group's net margin of 0.00%. ImmuCell's return on equity of 2.69% beat BGM Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
ImmuCell 2.57%2.69%1.76%

In the previous week, BGM Group had 1 more articles in the media than ImmuCell. MarketBeat recorded 2 mentions for BGM Group and 1 mentions for ImmuCell. BGM Group's average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score.

Company Overall Sentiment
BGM Group Neutral
ImmuCell Neutral

ImmuCell has lower revenue, but higher earnings than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$37.92M3.60-$19.94MN/AN/A
ImmuCell$27.64M3.22-$1.04M$0.08122.50

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ImmuCell
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

BGM Group has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Summary

ImmuCell beats BGM Group on 6 of the 11 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGM vs. The Competition

Export
MetricBGM GroupPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$126.37M$12.32B$7.16B$13.21B
Dividend YieldN/A2.64%2.53%16.37%
P/E RatioN/A797.58274.1526.16
Price / Sales3.60939.81635.98107.42
Price / CashN/A85.9776.3853.09
Price / Book0.0910.7111.216.34
Net Income-$19.94M$2.84B$3.50B$381.90M
7 Day Performance15.10%-0.93%-0.90%-1.41%
1 Month Performance30.02%-4.91%-4.44%-3.48%
1 Year Performance-96.16%-4.13%6.96%1.16%

BGM Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGM
BGM Group
0.3971 of 5 stars		$10.75
+7.9%		N/A-96.3%$126.37M$37.92MN/A471
PLYX
Polaryx Therapeutics
2.753 of 5 stars		$2.08
+0.6%		$7.67
+268.1%		N/A$103.84MN/AN/A11
PYPD
PolyPid
2.4569 of 5 stars		$5.23
-1.1%		$11.33
+116.6%		+52.3%$98.98MN/AN/A75
NTRB
Nutriband
0.9006 of 5 stars		$7.79
-5.6%		N/A-15.9%$94.65M$1.62MN/A3
CGTX
Cognition Therapeutics
1.7627 of 5 stars		$0.97
+1.3%		$3.33
+244.7%		-55.0%$91.95MN/AN/A14

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BGM) was last updated on 10/10/2026 by MarketBeat.com Staff.
From Our Partners
THE NEXT GREAT FINANCIAL CRISIS (it’s already here)
Weiss Ratings was the only independent firm to warn before the 2008 Financial Crisis. Now it is sounding the a...
Weiss Ratings | Sponsoredtc pixel
Inside the Options Play With a High Historical Win Rate
Ian Cooper's newest strategy targets triple-digit returns in just 9 days. It doesn't work every time, but a 73...
TradeWins | Sponsoredtc pixel
My next big call (under $1)
On the first day of October, one of the biggest banks in the world changed its mind about Bitcoin. Citigroup r...
Crypto 101 Media | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Tech expert smashes iPhone with golf club
Twenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...
Stansberry Research | Sponsoredtc pixel
Elon’s Hiding a Potential $20 Trillion Monster Inside Tesla
Elon Musk says there is a product inside Tesla's factories he calls the biggest ever made, ten times bigger th...
StocksToTrade | Sponsoredtc pixel
My biggest prediction yet?!
James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years lat...
Paradigm Press | Sponsoredtc pixel
Oil Surge Predicted…
Oil markets are heating up heading into 2026, and Marc Lichtenfeld, Chief Income Strategist at The Oxford Club...
The Oxford Club | Sponsoredtc pixel